advertisement

Aliskiren And Valsartan

54 %
46 %
advertisement
Information about Aliskiren And Valsartan

Published on October 13, 2008

Author: Chrishwilhelm

Source: slideshare.net

advertisement

Aliskiren and Valsartan for Antihypertensive Therapy Trial Presented at the American College of Cardiology Annual Scientific Session March 2007 Presented by Dr. Suzanne Oparil Aliskiren and Valsartan for Antihypertensive Therapy Trial

Aliskiren and Valsartan for Antihypertensive Therapy Trial: Background Valsartan is an angiotensin receptor blocker (ARB), and aliskiren is a new direct renin inhibitor that has just been approved by the US FDA. The goal of this trial was to evaluate treatment with aliskiren, valsartan, or the combination of the two compared with placebo among patients with mild to moderate hypertension. ACC 2007

Valsartan is an angiotensin receptor blocker (ARB), and aliskiren is a new direct renin inhibitor that has just been approved by the US FDA.

The goal of this trial was to evaluate treatment with aliskiren, valsartan, or the combination of the two compared with placebo among patients with mild to moderate hypertension.

Primary Endpoint: Reduction in mean sitting DBP Secondary Endpoint: Reduction in mean sitting SBP, response rate, achievement of blood pressure control (<140/90 mm Hg) 1797 patients of mean age 52 years with mild to moderate hypertension (diastolic blood pressure (DBP) > 95 and < 220 mm Hg) prior to randomization Placebo-controlled. Randomized. Blinded. Mean follow-up 8 weeks. 39% female. R mos. or yrs. follow-up Aliskiren and Valsartan for Antihypertensive Therapy Trial: Study Design 1-2 week period of washout from prior therapy and a 3-4 week run-in period Valsartan 160 mg n=455 Aliskiren + Valsartan 150 mg + 160 mg n=446 Placebo n=459 Aliskiren 150 mg n=437 Aliskiren 300 mg n=437 Valsartan 320 mg n=455 Aliskiren + Valsartan 300 mg + 320 mg n=446 Placebo n=459 4 weeks, double dosages 4 more weeks ACC 2007

Primary Endpoint: Reduction in mean sitting DBP

Secondary Endpoint: Reduction in mean sitting SBP, response rate, achievement of blood pressure control (<140/90 mm Hg)

Aliskiren and Valsartan for Antihypertensive Therapy: 4 Week Outcomes *p<0.0001 vs. placebo † p<0.001 vs. aliskiren/valsartan ACC 2007 Placebo Aliskiren + Valsartan Valsartan Aliskiren Week 4 Endpoint -10.7* -7.5* 150 mg n=437 -10.9* † -8.7* † 160 mg n=455 -15.3* -10.5* 150/160 mg n=446 -5.2 Change in SBP (mm Hg) -4.8 Change in DBP (mm Hg) n=459

Aliskiren and Valsartan for Antihypertensive Therapy: 8 Week Outcomes *p<0.0001 vs. placebo † p<0.001 vs. aliskiren/valsartan ACC 2007 -4.6 -17.2* -12.8* † -13.0* † Change in SBP (mm Hg) 16.5 49.3* 33.8 * † 37.4 * † BP Control Rate (%) Placebo Aliskiren + Valsartan Valsartan Aliskiren Week 8 Endpoint -9.0* † 300 mg n=437 -9.7* † 320 mg n=455 -12.2* 300/320 mg n=446 -4.1 Change in DBP (mm Hg) n=459

Aliskiren and Valsartan for Antihypertensive Therapy: Summary Among patients with mild to moderate hypertension, aliskiren, valsartan, and the combination of the two were associated with greater reductions in blood pressure compared with placebo at 8 wks, with the largest reductions seen in the combination group. Both aliskiren and valsartan are inhibitors of the renin-angiotensin-aldosterone system, but act at different points in the system, with aliskiren acting at the point of activation. ACC 2007

Among patients with mild to moderate hypertension, aliskiren, valsartan, and the combination of the two were associated with greater reductions in blood pressure compared with placebo at 8 wks, with the largest reductions seen in the combination group.

Both aliskiren and valsartan are inhibitors of the renin-angiotensin-aldosterone system, but act at different points in the system, with aliskiren acting at the point of activation.

Aliskiren and Valsartan for Antihypertensive Therapy: Summary Both agents were effective in reducing blood pressure, but the combination of the two agents appeared to be additive. Work is ongoing into whether there will be improved organ protection with aliskiren alone and in combination. ACC 2007

Both agents were effective in reducing blood pressure, but the combination of the two agents appeared to be additive.

Work is ongoing into whether there will be improved organ protection with aliskiren alone and in combination.

Add a comment

Related pages

Aliskiren/valsartan: Indications, Side Effects, Warnings ...

Easy to read patient leaflet for aliskiren/valsartan. Includes indications, proper use, special instructions, precautions, and possible side effects.
Read more

Aliskiren vs Valsartan - Posts about Drugs, Side effects ...

Which is better: Aliskiren or Valsartan? What is the difference between Valsartan and Aliskiren. 12 patient conversations comparing Valsartan and Aliskiren.
Read more

Aliskiren and valsartan combination therapy for the ...

Based on the established efficacy and safety profile of aliskiren/valsartan, ... NCBI > Literature > PubMed Central (PMC) Write to the Help Desk.
Read more

Buy Valturna (Aliskiren/Valsartan), Cheap Brand Valturna ...

Valturna (Aliskiren/Valsartan) and/or equivalents . Brand Name Options. Valturna 150/160mg from $3.23 USD/tablet. Manufactured by: Novartis Pharmaceutical
Read more

aliskiren and valsartan | Cigna

Aliskiren is an anti-hypertensive (blood pressure lowering) medication. It works by decreasing substances in the body that narrow blood vessels and raise ...
Read more

aliskiren and valsartan | University of Michigan Health System

Before you take aliskiren and valsartan, tell your doctor if you have kidney or liver disease, high levels of potassium in your blood (hyperkalemia), heart ...
Read more